CVKD (Cadrenal Therapeutics) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Debt-to-Asset?

Cadrenal Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Cadrenal Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Cadrenal Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $10.12 Mil. Cadrenal Therapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Cadrenal Therapeutics Debt-to-Asset Historical Data

The historical data trend for Cadrenal Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Debt-to-Asset Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-Asset

0.82

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Cadrenal Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Cadrenal Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadrenal Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Cadrenal Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cadrenal Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	10.124
	=	0.00

Cadrenal Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	10.124
	=	0.00

Cadrenal Therapeutics (NAS:CVKD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cadrenal Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029